ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SPRO vs OSTX // PIOTROSKI F-SCORE QUALITY

Spero Therapeutics Inc. (NASDAQ) VS. OS Therapies Incorporated (NYSE) • 15-METRIC TALLY: SPRO 5 — OSTX 0
▲ PIOTROSKI F-SCORE QUALITY LEADER: SPRO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPRO VS. OSTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SPRO OSTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 26.60% -35.00% +61.60 SPRO /roic <GO>
EV/EBITDA & P/E Valuation 5.1x — — TIE /valuation <GO>
Free Cash Flow Yield -19.53% -21.07% +1.54 SPRO /fcf-yield <GO>
Operating Margin 50.20% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 5/9 1/9 +4.00 SPRO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.6 28.5 +11.10 SPRO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $60.6M $59.8M $778.0K SPRO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SPRO REV OSTX REV SPRO GROSS % OSTX GROSS % SPRO FCF OSTX FCF
FY 2025 $12.6M $80.4M — — -$12.6M -$14.2M
FY 2024 $371.0K $19.1M — — -$23.4M -$7.3M
FY 2023 $933.0K $12.2M — — -$33.0M -$3.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPRO // BETA —
OSTX // BETA —